At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
trastuzumab +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/NEU-Overexpressed/Amplified Breast Cancer: Feasibility
In Brief
A Phase 2 clinical trial evaluating trastuzumab, cyclophosphamide, and 4 other interventions for Breast Cancer. Completed, enrolled 95 participants across 2 sites.
Detailed Summary
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedJun 2007
Primary CompletionJul 2011
TodayJul 2026
First PostedJun 5, 2007
Enrollment StartMar 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.1 years ago
Interventions
trastuzumabbiological
cyclophosphamidedrug
doxorubicin hydrochloridedrug
lapatinib ditosylatedrug
paclitaxeldrug
laboratory biomarker analysisother